CDP 855(CDP 855) - _专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

靶点-

作用方式-

作用机制

免疫抑制剂

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

器官移植排斥系统性红斑狼疮

原研机构

UCB Celltech

在研机构-

非在研机构

UCB Celltech

权益机构-

最高研发阶段终止药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 CDP 855 相关的临床结果

登录后查看更多信息

100 项与 CDP 855 相关的转化医学

登录后查看更多信息

100 项与 CDP 855 相关的专利（医药）

登录后查看更多信息

1

项与 CDP 855 相关的文献（医药）

2004-11-01·American Journal of Transplantation1区 · 医学

Treatment with Anti-MHC-Class-II Antibody Postpones Kidney Allograft Rejection in Primates but Increases the Risk of CMV Activation

1区 · 医学

Article

作者: Jan Ringers ; Eva-Maria Kuhn ; Roland Foulkes ; Margreet Jonker ; Bert 't Hart

Treatment of kidney graft recipients with antibodies that may specifically suppress the anti-donor response would be an ideal situation to prevent graft rejection. MHC class-II-specific antibodies and, in particular, DR specific antibodies have often been proposed as treatment to prevent antigen presentation, and thus graft destruction. Here we report an attempt to prevent graft rejection using a humanized MHC class-II-specific monoclonal antibody CDP855 in a cynomolgus monkey kidney graft model. A modest delay in graft rejection was observed when the antibody was given only on days 0, 1 and 2 after transplantation. Unexpectedly 50% of the animals succumbed of a viral infection, most likely CMV in two of three cases, prior to graft rejection in the first week post-transplantation. We speculate that the antibody treatment triggered CMV activation, possibly as a consequence of the activation of factors such as NF-kappab by the interaction of the antibody and its target cells.

100 项与 CDP 855 相关的药物交易

登录后查看更多信息